ANTHONY MELENDEZ

Anthony Melendez is a distinguished Managing Director at AbbVie Ventures, the corporate venture arm of the global biopharmaceutical company AbbVie. In this crucial role, Mr. Melendez is instrumental in sourcing, evaluating, and executing strategic investments in early-stage biotechnology and life sciences companies that are developing novel therapeutics and platform technologies. His work directly supports AbbVie's mission to discover and deliver innovative medicines that address serious health challenges.

At AbbVie Ventures, Anthony Melendez's investment focus spans a broad range of therapeutic areas, reflecting AbbVie's core research and development priorities. These include, but are not limited to, oncology, immunology, neuroscience, infectious diseases, and eye care. He seeks out companies with compelling scientific foundations, strong intellectual property, and experienced management teams poised to make a significant impact on patient care. His expertise lies in identifying disruptive technologies and scientific breakthroughs that have the potential to complement or expand AbbVie's existing pipeline and future strategic interests.

Mr. Melendez brings a robust career background to his position, combining deep scientific understanding with extensive business development and venture capital experience. Prior to his tenure at AbbVie Ventures, he honed his skills in various capacities within the pharmaceutical and biotechnology sectors, likely involving roles in corporate development, strategic planning, or research and development. This diverse background provides him with a unique perspective, enabling him to thoroughly assess both the scientific merit and commercial viability of potential investments. His leadership helps guide portfolio companies through critical development milestones, leveraging AbbVie's vast resources and expertise.

While specific individual investments are often part of a broader team effort at corporate venture funds, Anthony Melendez has been a key contributor to numerous investments within AbbVie Ventures' portfolio. These investments typically target companies developing first-in-class or best-in-class therapeutic candidates across various modalities, from small molecules to biologics and gene therapies. His contributions have been vital in fostering partnerships that accelerate the development of promising new treatments, ultimately aiming to bring life-changing medicines to patients worldwide. His strategic vision and commitment to innovation are central to AbbVie Ventures' success in the competitive landscape of life sciences venture capital.